ShiraTronics closes $33M Series A to fund neuromodulation devices for migraine; adds $3M

Recently founded implantable device start-up ShiraTronics Inc. (neuromodulation technologies) closed a $33M Series A financing round co-led by USVP, Amzak Health, and Strategic HealthCare Investment Partners; all three investors added a member to the board. Aperture Ventures, LivaNova PLC, and four other undisclosed backers (including one academic institution) also participated. The stealthy company, which was seeded earlier this year, is a 2018 spin-out from electrical medical device accelerator NuXcel. ShiraTronics' approach incorporates neuromodulation device technologies, which it plans to apply to the treatment migraine headaches.

Update 03/26/2020

ShiraTronics raised an additional $3M in the round from Breakout Ventures, USVP, Amzak Health, Strategic HealthCare Investment Partners, Aperture Ventures, LivaNova, and a leading academic institution. The new funds will help the company advance a migraine candidate into the clinic.